Chugai Seiyaku Kabushiki Kaisha

Satoshi Tanida

Satoshi Tsuchiya

Masahiro Nishimoto

Atsushi Matsuo

Hirotaka Kashiwagi

Yoshikazu Nishimura

Masahide Aoki

Nobuyuki Hori

Shoshin Yoshida

Takahiro Kawai

Hiroko Ogawa

Takuma Kamon

Kyoko Oguri

Tsutomu Sato

Hitoshi Yoshino

Yoshiyuki Furuta

Takuya Shiraishi

Kazuo Hattori

Toshiyuki Tsukaguchi

Takehiro Okada

Masaki Shibata

Osamu Kondoh

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

The present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof: 

1-(2H)-isoquinolone derivative

Growing community of inventors

Shizuoka, Japan

Satoshi Tanida